Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Imugene ( (AU:IMU) ) just unveiled an update.
Imugene Limited has launched a multi-instrument capital raising package comprising a two-tranche share placement of up to 66.7 million new shares at $0.18, a share purchase plan targeting about $8 million, and associated attaching and piggyback options. The offers, which also include SAR notes to CVI Investments Inc. and up to 66.6 million new warrants, are designed to strengthen Imugene’s balance sheet and broaden investor participation, potentially extending its funding runway and supporting ongoing operational and development activities.
The structure provides new and existing shareholders with equity and option exposure at set exercise prices out to 2027 and 2029, while the SAR notes and warrants add a layer of longer-dated, structured financing. By combining placements, a retail share purchase plan and commitment options for shortfall coverage, Imugene is seeking to secure diversified funding and reinforce market confidence in its capital position without relying solely on traditional equity issuance.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.18 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene Limited is a biotechnology company focused on developing immuno-oncology therapies, with its shares listed on the ASX. The company accesses capital markets to fund its clinical and commercial development programs, targeting investors in Australia and select institutional investors offshore.
Average Trading Volume: 1,509,113
Technical Sentiment Signal: Sell
Current Market Cap: A$57.87M
Learn more about IMU stock on TipRanks’ Stock Analysis page.